A Medicare beneficiary filling a specialty cancer prescription that costs $15,000 a year will, at some point in 2026, walk up to the pharmacy counter and owe nothing. Not a reduced copay. Not a percentage of the list price. Zero. That moment arrives when their qualifying out-of-pocket spending on covered Part D drugs crosses $2,100 for the calendar year. Every covered prescription after that is free of cost-sharing through December 31.
The Centers for Medicare & Medicaid Services confirmed the $2,100 threshold in its 2026 Part D redesign guidance. The figure is the inflation-adjusted successor to the $2,000 cap that first took effect in 2025 under the Inflation Reduction Act. CMS calculated the increase using an indexing formula written into the IRA itself, which ties the cap to the annual percentage increase in average spending on covered Part D drugs. Because the formula is statutory, the threshold adjusts automatically each year without new rulemaking or congressional action.
How the $2,100 cap works in practice
The redesigned Part D benefit is simpler than the old structure. Before the IRA, beneficiaries moved through a coverage gap (the “donut hole”) where they shouldered a larger share of costs, followed by a catastrophic phase where they still owed 5% of drug costs with no annual ceiling. The IRA overhauled that design entirely.
In 2026, most enrollees first pay a deductible of up to $590, then enter an initial coverage phase where they share costs with their plan. Once their true out-of-pocket spending (meaning what the beneficiary actually pays, not what the plan or manufacturer contributes) reaches $2,100, they enter the catastrophic phase.
In the catastrophic phase, beneficiary cost-sharing drops to $0, according to the CMS 2026 rate announcement. The transition is automatic. Enrollees do not need to file paperwork or call their plan. The plan’s tracking system registers when accumulated qualifying costs cross the line and adjusts cost-sharing at the pharmacy counter.
Behind the scenes, the financial burden shifts to other parties. According to the CMS Part D redesign fact sheet, in the catastrophic phase drug manufacturers cover 20% of costs through required discounts, plans absorb 60%, and the federal government pays the remaining 20% through reinsurance. That restructured liability split is what allows beneficiary cost-sharing to fall to zero.
The consumer-facing explanation on Medicare.gov states that beneficiaries will not have to pay out of pocket for covered Part D drugs after reaching the applicable threshold. That protection applies to every medication on the enrollee’s plan formulary for the rest of the calendar year. Drugs not listed on the formulary, premiums, and medications purchased outside the plan’s pharmacy network do not count toward the $2,100 limit and are not covered at zero cost-sharing even after the cap is reached.
Who is most likely to reach the cap
The $2,100 threshold matters most to beneficiaries with high prescription drug costs, particularly those taking specialty medications for cancer, rheumatoid arthritis, multiple sclerosis, hepatitis C, or other conditions where a single drug can carry a list price of $5,000 to $15,000 or more per month. Even with plan coverage absorbing a share, copays or coinsurance on these drugs can push a beneficiary past $2,100 within the first few months of the year.
Beneficiaries managing multiple chronic conditions with several brand-name drugs can also reach the cap, even if no single medication is extraordinarily expensive. Someone filling four or five brand-name prescriptions monthly, each with a $50 to $80 copay, could cross the threshold by mid-year.
CMS has estimated that the annual cap was designed to protect the roughly 1.5 million Part D enrollees who previously faced catastrophic-level drug costs each year with no spending ceiling, a figure drawn from the agency’s analyses of pre-IRA claims data. Granular projections tied specifically to the $2,100 figure for 2026 have not appeared in public CMS datasets as of July 2026, but the population of high-cost beneficiaries is expected to remain in that range.
Extra Help recipients and the cap
Beneficiaries enrolled in the Low-Income Subsidy program (also called Extra Help) already receive substantial cost-sharing assistance that, for most, keeps their out-of-pocket spending well below $2,100. For these enrollees, the cap functions as a backstop rather than a primary protection. Their copays on covered drugs are already reduced to a few dollars per prescription in many cases. The $2,100 cap is most consequential for beneficiaries who do not qualify for Extra Help but still face high drug costs, a group that includes many middle-income retirees on fixed incomes.
The monthly payment option many beneficiaries overlook
Reaching $2,100 in out-of-pocket costs does not mean a beneficiary must pay it all at the pharmacy counter in January or February. The Inflation Reduction Act also created the Medicare Prescription Payment Plan, which allows enrollees to spread their out-of-pocket drug costs across monthly installments throughout the year. A beneficiary who expects to hit the cap can opt into this program and pay a predictable monthly amount rather than absorbing large copays upfront when filling expensive prescriptions early in the year.
This installment option does not change the $2,100 cap itself. It changes the timing of payments, functioning like an interest-free payment plan administered through the Part D plan. Beneficiaries must opt in; enrollment is not automatic. Those who want to use it can sign up through their Part D plan or Medicare Advantage plan with drug coverage, and mid-year enrollment is permitted. Details are available through individual plan materials and through Medicare.gov.
What plans may adjust around the cap
The $2,100 cap shifts significant financial risk onto plan sponsors and manufacturers, and insurers have tools to respond. According to the CMS 2026 rate announcement, plan sponsors bear 60% of catastrophic-phase drug costs, a sharp increase from prior years. That added liability gives plans a financial incentive to manage utilization through formulary design. Plans may adjust formulary placement, moving certain drugs to higher cost-sharing tiers or tightening prior authorization requirements to manage the volume of claims that reach the catastrophic phase. They may also adjust premiums to offset the increased liability they absorb once enrollees cross the threshold.
As of July 2026, major Part D sponsors have not publicly isolated the impact of the catastrophic cap from other pricing decisions in their plan filings. Monthly premiums, tier structures, and formulary breadth all reflect a mix of factors, including drug price negotiations, rebate agreements, and competitive positioning, making it difficult to attribute any single change to the $2,100 threshold alone.
For beneficiaries, the practical takeaway is straightforward: review your plan’s formulary and cost-sharing structure during open enrollment each fall. A plan with lower premiums but higher copays on your specific drugs could push you toward the cap faster, which, counterintuitively, might work in your favor if you are certain to exceed $2,100 anyway. Conversely, a plan with higher premiums and lower copays might keep you below the cap but cost more overall. Running the numbers with your actual prescriptions, rather than relying on a plan’s star rating or premium alone, is the most reliable way to compare.
How the inflation-indexed cap could shift in future years
The $2,100 figure is not permanent. The IRA’s indexing formula ties the cap to growth in average Part D drug expenditures, meaning it will rise in future years if drug spending increases. If average expenditures grow faster than typical beneficiary income, a pattern consistent with historical drug spending trends, the cap could gradually erode in protective value for lower-income enrollees.
The reverse is also possible. If drug price reforms, including Medicare’s expanding authority to negotiate prices on select high-cost drugs, slow overall Part D spending growth, the cap could rise more gradually or hold relatively steady in inflation-adjusted terms.
For 2026, though, the math is settled. The cap is $2,100. Once a beneficiary reaches it, every covered drug on their plan’s formulary costs them nothing for the rest of the year. For the millions of Medicare enrollees who depend on expensive medications, that guarantee represents the most significant structural change to Part D since the program launched in 2006.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
